Mark Capone, MSc
Appointment: 28 January 2021
Background: Based in the US, Mark Capone is an accomplished life sciences executive. He spent over 17 years with Myriad Genetics, latterly as CEO and President, over which time he grew the company into a leading global precision medicine company. Prior to this Mark spent 17 years with Eli Lilly and Company in positions across the entire value chain. Mark is currently CEO of Precision Medicine Advisors, a consultancy for molecular diagnostics, pharmaceuticals, and biotechnology organizations, which he founded in 2020, and a non-executive of Nephrosant, a private US company focused on developing diagnostic tools for Chronic kidney Disease, and Microba, a precision microbiome science company.
Current external appointments: Mark is currently CEO of Precision Medicine Advisors and a non-executive director of Nephrosant and Microba.
Skills, experience and contribution: Mark has significant Life Science industry experience and of working in companies of different scale. He is an accomplished healthcare CEO with experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. He has extensive US public and private board experience across a large range of companies specializing in growth.